Sun, Apr 20, 2014, 12:54 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Aethlon Medical, Inc. Message Board

  • robert.vince robert.vince Nov 20, 2013 9:50 AM Flag

    AEMD: FDA Study, DARPA Milestones, Productive Operationally

    Aethlon Medical (OTC BB:AEMD) filed their 10-Q for the fiscal second quarter 2014 ending 9/30/2013 on November 14th. Revenue came at $645k and included $613k in DARPA related revenue and $32k in revenue for work under the subcontract agreement that the company has with Battelle related to the $22.8 million systems integrator contract with DARPA. Revenue was ahead of our $424k estimate ($404k DARPA + $20k Battelle) with the majority of the difference being that AEMD recognized revenue for three milestones for the Year 2 DARPA contract while we expected only two milestones to be booked in Q2. Through September AEMD had billed $3.4 million under the DAPRA awards, which represents $1.97 million under the initial year-1 contract and $1.42 million under the year-2 contract (worth $1.6 million and containing eight milestones), which was awarded to the company in August 2012. We assume that the final milestone under the year 2 contract (worth ~$200k) is billed and paid in fiscal Q3 (ending 12/31/2013). We also think that AEMD could book some revenue from the Year 3 contract, which was awarded to the company in September and will pay up to $1.53 million if all eight milestones are met, during the current fiscal year.

    We also model additional, although relatively minimal revenue from the Battelle contract throughout fiscal 2014. As a reminder, AEMD's subcontract is a time and materials contract so the total that AEMD will eventually bill will not be known until their work is completed. We do, however, think it's likely that there will be additional revenue contribution from this contract throughout the year.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • On the operational front, the last few months have been particularly productive. In addition to completing and receiving payment for DARPA milestones and commencing and being paid for work under the Battelle contract, AEMD officially launched their Exosome Sciences subsidiary and opened a lab in New Jersey where that business will work from. The company also announced that they expect to begin manufacturing the Hemopurifier to be used in the FDA approved study and further noted that they now have a processing technique that optimizes the ability of the affinity agent in the device to bind to blood borne viruses and pathogens. AEMD expects manufacturing to be completed by the current year-end. They expect patient treatment for the study to begin in Q1 2014.

      Noteworthy is that among the DARPA milestones completed in Q2 was one related to the capture of at least 90% of three or more targeted substances from the blood in 24 hours. The milestone paid in Q2 related to the year-2 DARPA contract is (per AEMD's 10-Q);

      Milestone 2.3.2.2 โ€“ Write and test software and conduct ergonomic research. Begin discussions with the systems integrator. The milestone payment was $195,581. Management considers this milestone to be substantive as it was not dependent on the passage of time nor was it based solely on another party's efforts. We obtained wrote and tested software and conducted ergonomic research and began discussions with the systems integrator. The report was accepted by the contracting officer's representative and the invoice was submitted thereafter.

      • 1 Reply to robert.vince
      • Milestone 2.3.3.2 โ€“ Cartridge construction with optimized affinity matrix design for each potential target. Complete the capture agent screening. The milestone payment was $208,781. Management considers this milestone to be substantive as it was not dependent on the passage of time nor was it based solely on another party's efforts. We completed the cartridge construction with optimized affinity matrix design for each potential target and completed the capture agent screening. The report was accepted by the contracting officer's representative and the invoice was submitted thereafter.

        Milestone M5 โ€“ Target capture 90% in 24 hours for at least three targets in blood or blood components. The milestone payment was $208,781. Management considers this milestone to be substantive as it was not dependent on the passage of time nor was it based solely on another party's efforts. We demonstrated that we were able to capture 90% in 24 hours for at least three of the agreed targets in blood or blood components. The report was accepted by the contracting officer's representative and the invoice was submitted thereafter.

        As a reminder, DARPA has the option of entering into the remainder of the proposed contract for years four and five, which would pay Aethlon up to an additional $1.7 million.

        Q2 operating expenses were $875k, well below our $1.2 million estimate and the lowest since fiscal Q2 2012 (ending 9/30/2011). This is a result of management's focus on conserving resources and keeping op expenses to a minimum as well as lower litigation and investor relations expense. This is the second straight quarter that op expenses have come in well below our estimate. Operating loss was just $230k, significantly better than our $756k loss estimate. Q2 net income and EPS were ($3.4) million and ($0.02) and included a $3.0 million non-cash expense related to change in derivative liability - which is a result of the increase in the common stock price through Q3.

 
AEMD
0.201+0.001(+0.50%)Apr 17 3:51 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.